Preview Mode Links will not work in preview mode

Medscape InDiscussion: Schizophrenia

Sep 13, 2022

Drs John Kane and Jonathan M. Meyer discuss what new antipsychotic drugs are available for schizophrenia. What drugs are under development? And what do they potentially offer?

Relevant disclosures can be found with the episode show notes on Medscape ( The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.


The Clozapine Handbook: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks) New Edition

The Clinical Use of Antipsychotic Plasma Levels: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks) Kindle Edition

Clinical Use of Reserpine in Psychiatry: Comparison With Chlorpromazine

Arvid Carlsson

Clozapine: Guidelines for Clinical Management

Clozapine: Medscape Drugs & Diseases

Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-analysis

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia — A Randomized Clinical Trial

Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities

Trace Amine-Associated Receptor 1 Modulates Dopaminergic Activity

A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

Emerging Schizophrenia Drugs Target Negative Symptoms

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia

Risperidone, 2 mg/day vs. 4 mg/day, in First-Episode, Acutely Psychotic Patients: Treatment Efficacy and Effects on Fine Motor Functioning